Sage Therapeutics Phase 2 Study Reinforces Cognitive Impact of Huntington’s Disease

Earlier this week Sage Therapeutics announced the results of their SURVEYOR study which quantified the cognitive impact of Huntington’s Disease.  Using the HD-Cognitive Assessment Battery (HD-CAB) they measured the difference between 29 healthy volunteers and 40 participants with HD.   As a secondary outcome the study measured the safety and tolerability of dalzanemdor and found that treatment with this oral medication was generally well tolerated, with no new safety signals.    The company is continuing to evaluate the SURVEYOR study data and plans to apply relevant learnings to ongoing work on the dalzanemdor program. 

Lesley White, Director of Pipeline Patient Engagement & Advocacy for Sage expressed her gratitude to the HD community saying ‘We would like to acknowledge the meaningful contributions of everyone who made this research possible. Sage is immensely grateful for the time and role played by study participants, family members, care partners, and advocates’

For further information, please see the press release.